In the Claims

1 (previously presented). A method of increasing the number of hematopoietic stem cells in peripheral blood of a patient, comprising administering an effective amount of an RNA interference molecule targeting SH2-domain containing inositol 5-phosphatase (SHIP) to the patient, wherein the number of hematopoietic stem cells in the peripheral blood of the patient is thereby increased.

2-17 (cancelled).

18 (previously presented). The method of claim 1, further comprising harvesting the hematopoietic stem cells from the patient after said administering.

19 (previously presented). The method of claim 18, wherein said harvesting comprises leukopheresis.

20 (previously presented). The method of claim 18, further comprising administering the harvested hematopoietic stem cells to the patient.

21 (cancelled).

22 (previously presented). The method of claim 1, wherein the RNA interference molecule is administered intravenously.

23 (cancelled).

24 (previously presented). The method of claim 1, wherein said administering mobilizes the hematopoietic stem cells to the peripheral blood.

25 (currently amended). The method of claim 1, wherein the patient has undergone myeloablation <u>prior to said administering</u>.

26 - 32 (cancelled).

33 (previously presented). The method of claim 1, wherein the RNA interference molecule is administered to the patient for 1 week or 2 weeks.

34 (cancelled).

35 (New). The method of claim 1, wherein the subject has cancer or an autoimmune deficiency.

36 (New). The method of claim 20, wherein the subject has cancer or an autoimmune deficiency.